FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018059462> ?p ?o ?g. }

• W2018059462 endingPage "255" @default.
• W2018059462 startingPage "249" @default.
• W2018059462 abstract "Objective. To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models. Methods. Patients with IB2 cervical cancers diagnosed from 1990 to 2000 were identified from tumor registries of two institutions. Patients were classified into risk groups: high-risk (HR) (positive nodes, parametria, or margins), intermediate-risk (IR) (positive lymph vascular space involvement (LVSI) with any cervical stromal invasion (CSI), or (−) LVSI and > middle- CSI), or low-risk (LR) (absence of HR or IR characteristics). Disease-free survival (DFS) was estimated by Kaplan–Meier method and comparisons between subgroups were studied by log rank. A Cox proportional hazards model was used to determine independent predictors of recurrence. Results. We identified 86 patients with stage IB2 tumors treated by RH. We found 34% of patients to be HR, 60% IR, and 6% LR. Of the 52 IR patients, 28 had (+) LVSI with superficial, middle, and outer 1/3 CSI, and 24 had (−) LVSI with middle or outer 1/3 invasion. Overall, postoperative adjuvant radiation (PRT) was used in 52% of the 86 patients, including 0/5 LR, 16/52 IR, and 29/29 HR patients. Univariate predictors of recurrence were pelvic nodal disease, (+) LVSI, (+) parametria, outer 1/3 CSI, and tumor size > 6 cm. Age, grade, histology, and the use of postoperative radiation were not associated with recurrence. Multivariate analysis identified LVSI as the only independent predictor of recurrence (RR 5.2, P = 0.03). Two-year DFS for LR, IR, and HR patients was 100%, 83%, and 60%, respectively. Only 4/24 (17%) IR patients with (−) LVSI got PRT compared with 12/28 (43%) of IR patients with (+) LVSI. The 2-year DFS for IR patients with (−) LVSI was 96%. IR (+) patients recurred more frequently with a 2-year DFS of 71%. Conclusions. Overall, 66% of patients with IB2 disease were classified as having low or intermediate-risk disease. IR patients with (−) LVSI and all LR patients did well with surgery alone. This study defines the independent importance of LVSI and questions the utility of published IR models when applied to stage IB2 cervical cancer." @default.
• W2018059462 created "2016-06-24" @default.
• W2018059462 creator A5008466254 @default.
• W2018059462 creator A5008763534 @default.
• W2018059462 creator A5017254635 @default.
• W2018059462 creator A5021105630 @default.
• W2018059462 creator A5028634420 @default.
• W2018059462 creator A5053990407 @default.
• W2018059462 creator A5057686070 @default.
• W2018059462 creator A5061736280 @default.
• W2018059462 creator A5062600036 @default.
• W2018059462 creator A5067793404 @default.
• W2018059462 creator A5081270131 @default.
• W2018059462 creator A5084542258 @default.
• W2018059462 creator A5090429618 @default.
• W2018059462 date "2004-08-01" @default.
• W2018059462 modified "2023-10-10" @default.
• W2018059462 title "Surgical–pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?" @default.
• W2018059462 cites W1995170578 @default.
• W2018059462 cites W1999738237 @default.
• W2018059462 cites W2013896394 @default.
• W2018059462 cites W2020434147 @default.
• W2018059462 cites W2038357623 @default.
• W2018059462 cites W2046631639 @default.
• W2018059462 cites W2054012747 @default.
• W2018059462 cites W2066179964 @default.
• W2018059462 cites W2070789376 @default.
• W2018059462 cites W2077598266 @default.
• W2018059462 cites W2091026040 @default.
• W2018059462 cites W2095028269 @default.
• W2018059462 cites W2109897652 @default.
• W2018059462 cites W2120405223 @default.
• W2018059462 cites W2134490068 @default.
• W2018059462 cites W2157719711 @default.
• W2018059462 cites W2328935341 @default.
• W2018059462 doi "https://doi.org/10.1016/j.ygyno.2004.05.038" @default.
• W2018059462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15297159" @default.
• W2018059462 hasPublicationYear "2004" @default.
• W2018059462 type Work @default.
• W2018059462 sameAs 2018059462 @default.
• W2018059462 citedByCount "32" @default.
• W2018059462 countsByYear W20180594622012 @default.
• W2018059462 countsByYear W20180594622013 @default.
• W2018059462 countsByYear W20180594622014 @default.
• W2018059462 countsByYear W20180594622016 @default.
• W2018059462 countsByYear W20180594622018 @default.
• W2018059462 countsByYear W20180594622020 @default.
• W2018059462 countsByYear W20180594622022 @default.
• W2018059462 crossrefType "journal-article" @default.
• W2018059462 hasAuthorship W2018059462A5008466254 @default.
• W2018059462 hasAuthorship W2018059462A5008763534 @default.
• W2018059462 hasAuthorship W2018059462A5017254635 @default.
• W2018059462 hasAuthorship W2018059462A5021105630 @default.
• W2018059462 hasAuthorship W2018059462A5028634420 @default.
• W2018059462 hasAuthorship W2018059462A5053990407 @default.
• W2018059462 hasAuthorship W2018059462A5057686070 @default.
• W2018059462 hasAuthorship W2018059462A5061736280 @default.
• W2018059462 hasAuthorship W2018059462A5062600036 @default.
• W2018059462 hasAuthorship W2018059462A5067793404 @default.
• W2018059462 hasAuthorship W2018059462A5081270131 @default.
• W2018059462 hasAuthorship W2018059462A5084542258 @default.
• W2018059462 hasAuthorship W2018059462A5090429618 @default.
• W2018059462 hasConcept C121608353 @default.
• W2018059462 hasConcept C126322002 @default.
• W2018059462 hasConcept C141071460 @default.
• W2018059462 hasConcept C143998085 @default.
• W2018059462 hasConcept C144301174 @default.
• W2018059462 hasConcept C146357865 @default.
• W2018059462 hasConcept C151730666 @default.
• W2018059462 hasConcept C2777088508 @default.
• W2018059462 hasConcept C2778220009 @default.
• W2018059462 hasConcept C2910227796 @default.
• W2018059462 hasConcept C38180746 @default.
• W2018059462 hasConcept C50382708 @default.
• W2018059462 hasConcept C71924100 @default.
• W2018059462 hasConcept C86803240 @default.
• W2018059462 hasConcept C90924648 @default.
• W2018059462 hasConceptScore W2018059462C121608353 @default.
• W2018059462 hasConceptScore W2018059462C126322002 @default.
• W2018059462 hasConceptScore W2018059462C141071460 @default.
• W2018059462 hasConceptScore W2018059462C143998085 @default.
• W2018059462 hasConceptScore W2018059462C144301174 @default.
• W2018059462 hasConceptScore W2018059462C146357865 @default.
• W2018059462 hasConceptScore W2018059462C151730666 @default.
• W2018059462 hasConceptScore W2018059462C2777088508 @default.
• W2018059462 hasConceptScore W2018059462C2778220009 @default.
• W2018059462 hasConceptScore W2018059462C2910227796 @default.
• W2018059462 hasConceptScore W2018059462C38180746 @default.
• W2018059462 hasConceptScore W2018059462C50382708 @default.
• W2018059462 hasConceptScore W2018059462C71924100 @default.
• W2018059462 hasConceptScore W2018059462C86803240 @default.
• W2018059462 hasConceptScore W2018059462C90924648 @default.
• W2018059462 hasIssue "2" @default.
• W2018059462 hasLocation W20180594621 @default.
• W2018059462 hasLocation W20180594622 @default.
• W2018059462 hasOpenAccess W2018059462 @default.
• W2018059462 hasPrimaryLocation W20180594621 @default.
• W2018059462 hasRelatedWork W1984291133 @default.

• next